These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

350 related items for PubMed ID: 33171005

  • 21. Letermovir Prophylaxis for CMV Reactivation in Allogeneic Stem Cell Recipients: A Retrospective Single Center Analysis.
    Koch K, Osswald L, Miller I, Braitsch K, Götze K, Bassermann F, Herhaus P, Verbeek M.
    Anticancer Res; 2022 Nov; 42(11):5431-5441. PubMed ID: 36288861
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Role of letermovir for prevention of cytomegalovirus infection after allogeneic haematopoietic stem cell transplantation.
    Razonable RR.
    Curr Opin Infect Dis; 2018 Aug; 31(4):286-291. PubMed ID: 29746444
    [Abstract] [Full Text] [Related]

  • 24. Features of cytomegalovirus DNAemia and virus-specific T-cell responses in allogeneic hematopoietic stem-cell transplant recipients during prophylaxis with letermovir.
    Giménez E, Guerreiro M, Torres I, Aguilar C, Albert E, Hernández-Boluda JC, Hernani R, Pérez A, Amat P, Piñana JL, Montoro J, Solano C, Navarro D.
    Transpl Infect Dis; 2023 Apr; 25(2):e14021. PubMed ID: 36748748
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Letermovir: First Global Approval.
    Kim ES.
    Drugs; 2018 Jan; 78(1):147-152. PubMed ID: 29288370
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Letermovir safety and efficacy for cytomegalovirus prophylaxis in adult Japanese kidney transplant recipients: a multicenter, open-label, noncomparative Phase 3 study.
    Ishida H, Goto N, Imamura R, Sasaki H, Unagami K, Futamura K, Murata Y, Oshima N, Eto T, Haber B.
    Clin Exp Nephrol; 2024 Aug; 28(8):822-831. PubMed ID: 38615067
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Refractory and Resistant Cytomegalovirus After Hematopoietic Cell Transplant in the Letermovir Primary Prophylaxis Era.
    Sassine J, Khawaja F, Shigle TL, Handy V, Foolad F, Aitken SL, Jiang Y, Champlin R, Shpall E, Rezvani K, Ariza-Heredia EJ, Chemaly RF.
    Clin Infect Dis; 2021 Oct 20; 73(8):1346-1354. PubMed ID: 33830182
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Effective Letermovir Prophylaxis of CMV infection post allogeneic hematopoietic cell transplantation: Results from the French temporary authorization of use compassionate program.
    Beauvais D, Robin C, Thiebaut A, Alain S, Coiteux V, Ducastelle-Lepretre S, Marçais A, Ceballos P, Xhaard A, Redjoul R, Nguyen S, Brissot E, Joris M, Turlure P, Rubio MT, Chevallier P, Bénard N, Liautard C, Yakoub-Agha I.
    J Clin Virol; 2022 Mar 20; 148():105106. PubMed ID: 35182958
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Letermovir in lung transplant recipients with cytomegalovirus infection: A retrospective observational study.
    Veit T, Munker D, Barton J, Milger K, Kauke T, Meiser B, Michel S, Zoller M, Nitschko H, Keppler OT, Behr J, Kneidinger N.
    Am J Transplant; 2021 Oct 20; 21(10):3449-3455. PubMed ID: 34118118
    [Abstract] [Full Text] [Related]

  • 35. Letermovir prophylaxis for cytomegalovirus in lung-transplant recipients: a comprehensive study with literature review of off-label use and real-world experiences.
    Hirama T, Shundo Y, Watanabe T, Ohsumi A, Watanabe T, Okada Y.
    Clin Exp Med; 2024 Apr 05; 24(1):68. PubMed ID: 38578337
    [Abstract] [Full Text] [Related]

  • 36. Letermovir at a Prophylactic Dose for Cytomegalovirus Infection in Children Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Retrospective Study in Japan.
    Tatebe Y, Manabe Y, Tanaka Y, Shiwaku T, Ochi M, Tamefusa K, Ishida H, Fujiwara K, Washio K, Hamano H, Murakawa K, Zamami Y.
    Biol Pharm Bull; 2024 Apr 05; 47(9):1575-1582. PubMed ID: 39343543
    [Abstract] [Full Text] [Related]

  • 37. Human herpesvirus-6 reactivation and disease after allogeneic haematopoietic cell transplantation in the era of letermovir for cytomegalovirus prophylaxis.
    Kampouri E, Zamora D, Kiem ES, Liu W, Ibrahimi S, Blazevic RL, Lovas EA, Kimball LE, Huang ML, Jerome KR, Ueda Oshima M, Mielcarek M, Zerr DM, Boeckh MJ, Krantz EM, Hill JA.
    Clin Microbiol Infect; 2023 Nov 05; 29(11):1450.e1-1450.e7. PubMed ID: 37532126
    [Abstract] [Full Text] [Related]

  • 38. [Management of cytomegalovirus infection after hematopoietic stem cell transplantation].
    Mori T.
    Rinsho Ketsueki; 2019 Nov 05; 60(9):1337-1340. PubMed ID: 31597861
    [Abstract] [Full Text] [Related]

  • 39. Letermovir for Secondary Prophylaxis of Cytomegalovirus Infection and Disease after Allogeneic Hematopoietic Cell Transplantation: Results from the French Compassionate Program.
    Robin C, Thiebaut A, Alain S, Sicre de Fontbrune F, Berceanu A, D'Aveni M, Ceballos P, Redjoul R, Nguyen-Quoc S, Bénard N, Pahlavan-Grumel G, Cordonnier C.
    Biol Blood Marrow Transplant; 2020 May 05; 26(5):978-984. PubMed ID: 32035273
    [Abstract] [Full Text] [Related]

  • 40. Letermovir for Cytomegalovirus infection in pediatric patients undergoing allogenic hematopoietic stem cell transplantation: a real-life study by the Infectious Diseases Working Group of Italian Association of Pediatric Hematology-Oncology (AIEOP).
    Galaverna F, Baccelli F, Zama D, Tridello G, Masetti R, Soncini E, Mura R, Barzaghi F, Colombini A, Prunotto G, D'Amico MR, Calore E, Biffi A, Perruccio K, Gasperini P, Oltolini C, Quagliarella F, Giacomazzi A, Pagliara D, Locatelli F, Cesaro S.
    Bone Marrow Transplant; 2024 Apr 05; 59(4):505-512. PubMed ID: 38272999
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.